The global economic burden of antibiotic-resistant infections and the potential impact of bacterial vaccines: a modelling study

Antibiotic resistance (ABR) can increase hospital costs, utility loss, and mortality risk per patient. Understanding these losses is crucial for tackling ABR efficiently. A study estimated the global economic burden of antibiotic-resistant infections and the potential for bacterial vaccines to mitigate this burden. Multidrug-resistant tuberculosis had the highest mean hospital cost attributable to ABR per patient, with carbapenem-resistant infections having the highest cost-per-case. ABR is associated with a median value of US$693 billion in hospital costs globally, with US$207 billion potentially avertable by vaccines.